Translational Regenerative Medicine: Market Prospects 2012-2022

August 2012 | 193 pages | ID: T9FF81F4D7CEN
Visiongain

Abstracts

See what the future holds for translational regenerative medicine. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product and regional level to 2022.

There you investigate the most lucrative areas in that research field, industry and market. Discover prospects for tissue-engineered products, stem cell treatments and gene therapy.

We pack our study with information and analysis to help your work and save you time:

• Access to present and predicted trends, with commercial opportunities and prospects revealed
• Data and discussions - including our revenue forecasts to 2022 - for your research, analyses and decision making
• Tables, charts and lists to benefit your reports, proposals and presentations.

In our investigation you also see qualitative analyses, news, R&D and business developments. You receive 48 tables, 39 charts and two research interviews.

The following sections highlight what you discover in that report.

YOU FIND PROSPECTS FOR SUBMARKETS AND PRODUCTS

In addition to analyses of the overall world market, you see revenue forecasting of four world-level submarkets to 2022:

• Tissue-engineered products
• Stem cell applications
• Gene therapy
• Other uses.

Also, how will four leading products - Apligraf, Dermagraft, DeNovo NT and Osteocel Plus - perform to 2022? You find business research and analysis with individual revenue forecasts and discussions. See prospects for the products.

Our report also breaks the overall world market into regional analyses.

WHAT ARE THE PROSPECTS IN LEADING REGIONS AND COUNTRIES?

There are many commercial opportunities in developed and developing countries. You discover individual revenue forecasts to 2022 for regions, with discussions of countries:

• United States
• Europe - EU, Norway, Switzerland and Iceland
• Asia Pacific - including Japan, China, India and South Korea
• Rest of the world - including Brazil and Russia.

Revenues in many countries will multiply many times from 2012 to 2022, our analyses show. The US market dominates in 2012, giving more than 60% of revenues.

This decade, product launches will benefit regional and national markets.

RESEARCH AND DEVELOPMENT - POTENTIAL IN THIS EMERGING INDUSTRY

What's happening in the R&D pipeline for translational regenerative medicine? Our study shows you developmental trends:

• Diabetes treatments
• Cardiological and cardiovascular therapies
• Cancer therapy
• Ocular (ophthalmological) uses - treating eye diseases.

You discover how science and technology change that field and market. Biology, medicine and engineering combine. Our investigation shows you trends and outlooks, exploring matters affecting the sector.

WHAT ISSUES AFFECT THE REGENERATIVE TREATMENTS INDUSTRY AND MARKET?

Our study lets you assess industry trends and outlooks. There you find discussions, including qualitative analyses:

• Tissue engineering, organogenesis and organ transplants
• Autologous chondrocyte implantation (ACI)
• Haematopoietic stem cell transplantation and other cellular treatments
• Orthobiologics, biomaterials, neuroprotection and nanotechnology
• Gene therapy, including delivery and viral vectors
• Bone marrow material and human embryonic stem cells
• Mesenchymal stem cell technologies
• Skin regeneration, wound repair, cosmetic uses and treating degenerative disorders
• Treatment of leg ulcers, cartilage, livers, hearts and eyes
• Regulations, reimbursement and patents - safety, patient access and intellectual property (IP).

You see discussions of technological, commercial and economic matters, with emphasis on organisations developing the technologies. Discover existing and potential gains.

LEADING COMPANIES AND POTENTIAL FOR MARKET GROWTH

What will happen next in regenerative science and technology? This decade, that sector of biotechnology will flourish - already there are products on sale and clinical trials underway.

The R&D pipeline is strong and promising. Overall world revenue for that market area will reach $1.4bn in 2012, our report forecasts. There will be high demand for treatments, with degenerative diseases, wound healing and other applications stimulating progress.

There are many challenges to overcome, but that industry and market is succeeding. In our study you find discussions of 27 leading organisations, including these:

• Shire Regenerative Medicine
• Advanced Cell Technology
• Athersys
• Geron
• Ceregene
• Cytori Therapeutics
• Fibrocell Science
• Mesoblast
• Zimmer
• Opexa Therapeutics.

You see details of products, R&D and commercial outlooks. This decade, many opportunities will arise, including investments by pharmaceutical companies.

NINE WAYS TRANSLATIONAL REGENERATIVE MEDICINE: MARKET PROSPECTS 2012-2022 HELPS YOU

To summarise, our report gives you the following knowledge on the topic:

• Forecasted revenues to 2022 for the overall world market and 4 submarkets
• Potential revenues of 4 leading marketed products to 2022
• Market forecasting to 2022 for leading regions - US, Europe and Asia Pacific
• Profiles of 27 leading companies - discussions of activities, products and outlooks
• Reviews of R&D pipelines and emerging players - progress and trends
• Opinions on the sector, including our interviews with authorities in the field
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market
• Prospects for established companies and those seeking to launch products.

Contents

1. EXECUTIVE SUMMARY

1.1 Regenerative Medicine Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. TRANSLATIONAL REGENERATIVE MEDICINE: AN INTRODUCTION

2.1 Regenerative Medicine
2.2 Stem Cell Therapy
2.3 Gene Therapy
  2.3.1 Gene Delivery and Viral Vectors
2.4 Tissue Engineering
2.5 Small Molecules and Proteins - Enhancing Regenerative Medicine
2.6 Cosmetic Applications for Regenerative Medicine
2.7 Translational Regenerative Medicine
  2.7.1 Scope of this Report
  2.7.2 Products Not Covered by this Report

3. THE GLOBAL REGENERATIVE MEDICINE MARKET 2012-2022

3.1 Global Regenerative Medicine Market 2011
  3.1.1 Global Regenerative Medicine Market Forecast 2012-2022
3.2 Tissue Engineered Products 2011
  3.2.1 Apligraf (Organogenesis) Sales Forecast 2012-2022
  3.2.2 Dermagraft (Advanced BioHealing/Shire Regenerative Medicine) Sales Forecast 2012-2022
  3.2.3 Autologous Chondrocyte Implantation (ACI)
    3.2.3.1 ChondroCelect (TiGenix)
    3.2.3.2 Carticel (Genzyme)
    3.2.3.3 MACI (Genzyme)
    3.2.3.4 ACI Pipeline 2012
  3.2.4 DeNovo NT (Zimmer/ISTO Technologies) Sales Forecast 2012-2022
  3.2.5 ReCell (Avita Medical)
  3.2.6 MySkin and CyroSkin (Altrika)
  3.2.7 Acellular Products in Tissue Engineering
  3.2.8 Tissue Engineered Products Market Forecast 2012-2022
3.3 Stem Cell Therapy 2012
  3.3.1 Haematopoietic Stem Cell Transplantation Market 2011
  3.3.2 Stem Cell Orthobiologics 2011
    3.3.2.1 Orthobiologics
  3.3.3 Osteocel Plus (NuVasive/Osiris Therapeutics) Sales Forecast 2012-2022
  3.3.4 Trinity Evolution (Orthofix)
  3.3.5 LiquidGen (Skye Orthobiologics)
  3.3.6 AlloStem (AlloSource)
  3.3.7 PureGen (AlphaTec Spine)
  3.3.8 Other Approved Stem Cell Therapy Products
    3.3.8.1 Prochymal (Osiris)
  3.3.9 Late-Stage Pipeline for Stem Cell Therapeutics
  3.3.10 Stem Cell Therapy Market Forecast 2012-2022
3.4 Gene Therapy Market 2011
  3.4.1 Asian Gene Therapy Market
  3.4.2 Neovasculgen (OJSC HSCI) - First Gene Therapy in Russia
  3.4.3 Near-Term Gene Therapy Pipeline
  3.4.4 Glybera (UniQure)
  3.4.5 Collategene (Beperminogene Perplasmid, Vical/AnGes MG)
  3.4.6 Allovectin-7 (Vical)
  3.4.7 Trinam (Taberminogene Vadenovec, Ark Therapeutics)
  3.4.8 Gene Therapy Market Forecast 2012-2022
  3.4.9 Gene Therapy Late-Stage Failures
3.5 Other Cellular Regenerative Medicine Products Market Forecast 2012-2022
  3.5.1 Provenge (Dendreon)
  3.5.2 LAVIV (Azficel-T, Fibrocell Science)

4. LEADING REGENERATIVE MEDICINE COMPANIES

4.1 Aastrom Biosciences - Lxmyelocel-T for Critical Limb Ischemia
4.2 Shire Regenerative Medicine - a Leader in Regenerative Medicine
4.3 Advanced Cell Technology - Leading Stem Cell Research
4.4 Altrika
4.5 Athersys - MultiStem
4.6 Ark Therapeutics
4.7 Avita Medical
4.8 AxoGen
4.9 BioDlogics
4.10 BioSante Pharmaceuticals
4.11 Ceregene and CNS Gene Therapy
4.12 Cytori Therapeutics
4.13 Cold Genesys - Cancer Immunotherapy
4.14 Dendreon - Targeting Cancer
4.15 Fibrocell Science
4.16 Genzyme
  4.16.1 Epicel (Genzyme)
4.17 Geron
4.18 Mesoblast - Development in Stem Cell Therapies
4.19 Opexa Therapeutics
4.20 Organogenesis
4.21 Osiris Therapeutics - Mesenchymal Stem Cells Technology
4.22 Oxford BioMedica - LentiVector Gene Delivery Platform
4.23 ReNeuron
4.24 SpineSmith Partners
4.25 Tengion
4.26 TiGenix
  4.26.1 TiGenix and Cellerix
4.27 UniQure
  4.27.1 Haemophilia B
4.28 Zimmer and ISTO Technologies

5. LEADING APPLICATIONS FOR REGENERATIVE MEDICINE 2012-2022

5.1 Tissue Engineering Applications
  5.1.1 Tissue Engineering for Skin Diseases or Injuries
    5.1.1.1 Diabetic Foot and Venous Leg Ulcers
  5.1.2 Tissue Engineering for Cartilage Replacement
  5.1.3 Tissue Engineering for Liver Disease
  5.1.4 Tissue Engineering for Cardiovascular Disease
  5.1.5 Tissue Engineering for Eye Diseases
  5.1.6 Organ Transplants
5.2 Stem Cell Therapy Applications
  5.2.1 Diabetes and Stem Cell Therapy
    5.2.1.1 ViaCyte
    5.2.1.2 Cellonis Biotechnology - Commercialising Diabetes Research on Stem Cells
    5.2.1.3 Ixion Biotechnology - Insulin Producing Stem Cells
    5.2.1.4 Novo Nordisk and Cellartis
    5.2.1.5 AstraZeneca
    5.2.1.6 Eli Lilly
    5.2.1.7 Other Stem Cell Diabetes Developments
  5.2.2 Stem Cell Therapy for Cardiovascular Disease
    5.2.2.1 Revascor (Mesoblast)
    5.2.2.2 Cardio3 BioSciences
    5.2.2.3 MediStem
    5.2.2.4 NeoStem
  5.2.3 Stem Cell Therapy in Cancer
    5.2.3.1 Amgen -Treatment of Metastatic Renal Cell Carcinoma
    5.2.3.2 Cellerant Therapeutics
    5.2.3.3 OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
  5.2.4 Stem Cell Therapy for CNS Conditions
    5.2.4.1 Neuralstem - Synaptic Repair and Neuroprotection
    5.2.4.2 BrainStorm Cell Therapeutics -Treatment of Spinal Cord Injury and ALS
  5.2.5 Stem Cell Therapy for Treating Ocular Diseases
    5.2.5.1 Advanced Cell Technology - Developments in Treating Ocular Diseases
    5.2.5.2 EyeCyte
    5.2.5.3 ArBlast - Treating Corneal Disorders
    5.2.5.4 Pfizer - Age-Related Macular Degeneration Collaboration
5.3 Gene Therapy Applications
  5.3.1 Diabetes and Gene Therapy
  5.3.2 Cancer and Gene Therapy
    5.3.2.1"Suicide Gene" Induces Thymidine Kinase Production
  5.3.3 Neurodegenerative Diseases and Gene Therapy
  5.3.4 Gene Therapy for Eye Diseases
  5.3.5 Gene Therapy for Haemophilia B

6. TRENDS IN TRANSLATIONAL REGENERATIVE MEDICINE 2012-2022

6.1 SWOT Analysis for Translational Regenerative Medicine 2012-2022
  6.1.1 Drivers and Restraints for Translational Regenerative Medicine 2012-2022
  6.1.2 Market Strengths: Proven Clinical and Commercial Value
  6.1.3 Strengths in Stem Cells
  6.1.4 Big Pharma Investment to Drive Growth
    6.1.4.1 Stem Cell Therapy Investments
    6.1.4.2 Gene Therapy Investments
    6.1.4.3 Tissue Engineering Investments
  6.1.5 Market Weaknesses: A Field Still in its Infancy
  6.1.6 Market Opportunities and Threats
  6.1.7 Regulatory Hurdles Must be Overcome
  6.1.8 Stem Cell Regulation in the US
  6.1.9 Commercialising Regenerative Medicine Will be Challenging
  6.1.10 Medical Tourism - Opportunities and Threats
  6.1.11 Immune Response Challenges
    6.1.11.1 Graft Versus Host Disease (GvHD)
    6.1.11.2 Gene Therapy and Immune Response
6.2 STEP Analysis for Translational Regenerative Medicine 2012-2022
6.3 Social Factors
  6.3.1 Ethical Concerns with Regenerative Medicine
6.4 Technological Developments
  6.4.1 Nanotechnology in Regenerative Medicine
  6.4.2 Manufacturing and Scalability
    6.4.2.1 Bioreactors - Making Scale up Feasible
6.5 Economic Pressures
  6.5.1 High Rewards Achievable
  6.5.2 Government and Public Funding for Regenerative Medicine
    6.5.2.1 California Institute for Regenerative Medicine (CIRM)
    6.5.2.2 Regenerative Medicine Promotion Act
    6.5.2.3 European REMEDiE Project
6.6 Political Issues
  6.6.1 Regenerative Medicine Reimbursement
    6.6.1.1 Reimbursement in the US
    6.6.1.2 Reimbursement in the EU
  6.6.2 The Intellectual Property Landscape
    6.6.2.1 EU and Human Embryonic Stem Cells
    6.6.2.2 US Law of Nature - Gene Patents

7. REGIONAL ANALYSIS OF THE REGENERATIVE MEDICINE MARKET 2012-2022

7.1 Regional Breakdown of the Regenerative Medicine Market 2011
7.2 Regional Regenerative Medicine Market Forecast 2012-2022
7.3 US Market Overview 2011
  7.3.1 US Regenerative Medicine Regulation
  7.3.2 US Regenerative Medicine Market Forecast 2012-2022
7.4 European Market Overview 2011
  7.4.1 European Regenerative Medicine Regulation
  7.4.2 Europe: Mixed Responses
  7.4.3 European Regenerative Medicine Market Forecast 2012-2022
7.5 Asia Pacific Market Overview 2011
  7.5.1 Japan
  7.5.2 China
  7.5.3 India
  7.5.4 South Korea: First to Approve Stem Cell Treatments
  7.5.5 Asia Pacific Regenerative Medicine Market Forecast 2012-2022
7.6 Rest of World (RoW) Market Forecast 2012-2022
  7.6.1 Brazil
  7.6.2 Russia

8. OPINIONS FROM OUR SURVEY: RESEARCH INTERVIEWS

8.1 Interview with Professor Francois Berthiaume, Associate Professor of Biomedical Engineering, Rutgers University, New Jersey
  8.1.1 Thoughts on the Current State of Regenerative Medicine
  8.1.2 Thoughts on Stem Cell Developments
  8.1.3 Challenges in the Tissue Engineering Market
  8.1.4 Thoughts on Future Developments
8.2 Interview with David Pernock, Chairman and CEO, Fibrocell Science
  8.2.1 Thoughts on the Regenerative Medicine Market
  8.2.2 Aesthetic Treatments
  8.2.3 Challenges for Cosmetic Treatments
  8.2.4 Drivers and Threats

9. CONCLUSIONS

9.1 Regenerative Medicine Market in 2011
  9.1.1 Growth and Opportunities in Developing Regenerative Medicines 2012-2022
  9.1.2 US Tissue Engineering Market Leads the Way
  9.1.3 Commercial Success and Approval Will Drive Market

List Of Tables

LIST OF TABLES

Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Potency and Source of Stem Cells
Table 3.1 Regenerative Medicine: World Market Forecast by Sector, ($m), AGR (%), CAGR (%), 2011-2022
Table 3.2 Regenerative Medicine: World Market Forecast by Product, ($m), AGR (%), CAGR (%), 2011-2022
Table 3.3 Regenerative Medicine: World Market Shares by Sector (%), 2011, 2017 & 2022
Table 3.4 Tissue Engineered Products: World Revenue ($m) and Market Shares (%), 2011
Table 3.5 Apligraf Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.6 Dermagraft Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.7 DeNovo NT Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.8 Tissue Engineered Products: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.9 Tissue Engineered Products: Market Forecast by Product ($m), AGR (%), CAGR (%), 2011-2022
Table 3.10 Orthobiologics Market: Segment Revenues ($bn) and Market Shares (%), 2011
Table 3.11 Osteocel Plus Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.12 Other Approved Stem Cell Products, 2011-2022
Table 3.13 Late Stage Clinical Trials for Stem Cell Therapeutic Products, 2012
Table 3.14 Stem Cell Therapy: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.15 Stem Cell Therapy: Market Forecast by Product ($m), AGR (%), CAGR (%), 2011-2022
Table 3.16 AnGes MG Collategene Pipeline, 2012
Table 3.17 Vical Pipeline, 2012
Table 3.18 Gene Therapy: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 3.19 Selected Gene Therapy Failures, 2008-2011
Table 3.20 Other Cell Therapy Products: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 4.1 Aastrom Biosciences' Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.2 Selected Ark Therapeutics Pipeline Products, 2012
Table 4.3 Avita Medical Regenerative Medicine Revenue ($m), AGR (%), 2009-2011
Table 4.4 BioSante Pharmaceuticals: Selected GVAX Clinical Trials, 2012
Table 4.5 Ceregene Gene Therapy Pipeline, 2012
Table 4.6 Cytori Therapeutics' Currently-Listed Clinical Trials Involving Stem Cell Therapies, 2012
Table 4.7 Genzyme: Carticel, Epicel and MACI Global Sales ($m), AGR (%), 2009-2011
Table 4.8 Mesoblast's Currently-Listed Clinical Trials Involving Stem Cells, 2012
Table 4.9 Osiris Therapeutics Stem Cell Pipeline, 2012
Table 4.10 Selected Oxford Biomedica Pipeline Products, 2012
Table 4.11 Tengion Product Pipeline, 2012
Table 4.12 TiGenix Product Sales ($m), AGR (%), 2009-2011
Table 4.13 Selected UniQure Pipeline Products, 2012
Table 5.1 Leading Regenerative Medicine Indications: Latest Development Stage, 2011
Table 5.2 Selected Companies Developing Stem Cell Diabetes Treatments, 2012
Table 5.3 Selected Companies Developing Stem Cell Cardiological/Cardiovascular Treatments, 2012
Table 5.4 Selected Companies Developing Stem Cell Treatments for Cancer, 2012
Table 5.5 Selected Companies Developing Stem Cell Ocular Treatments, 2012
Table 6.1 Regenerative Medicine: SWOT Analysis, 2012-2022
Table 6.2 CIRM Funding by Disease, 2004-2011
Table 7.1 Regenerative Medicine: World Market Forecast by Region ($m), AGR (%), CAGR (%), 2011-2022
Table 7.2 Regenerative Medicine: World Market Shares by Region (%), 2011, 2017 & 2022
Table 7.3 US Regenerative Medicine: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 7.4 Regenerative Medicine in Europe: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 7.5 Asia Pacific Regenerative Medicine: Market Forecast ($m), AGR (%), CAGR (%), 2011-2022
Table 7.6 Rest of World Regenerative Medicine: Market Forecast ($m), AGR (%), CAGR (%) 2011-2022

List Of Figures

LIST OF FIGURES

Figure 2.1 A History of Gene Therapy, 1970-2012
Figure 2.2 Examples of FDA-Approved Tissue Engineered Products
Figure 3.1 Regenerative Medicine Therapies: Developed Market Status, 2012
Figure 3.2 Regenerative Medicine: World Market Forecast ($m), 2011-2022
Figure 3.3 Regenerative Medicine: World Market Shares by Sector (%), 2011
Figure 3.4 Regenerative Medicine: World Market Shares by Sector (%), 2017
Figure 3.5 Regenerative Medicine: World Market Shares by Sector (%), 2022
Figure 3.6 Tissue Engineered Products: World Market Shares (%), 2011
Figure 3.7 Apligraf Revenue Forecast ($m), 2011-2022
Figure 3.8 Dermagraft Revenue Forecast ($m), 2011-2022
Figure 3.9 Dermagraft Drivers and Restraints, 2012-2022
Figure 3.10 DeNovo NT Revenue Forecast ($m), 2011-2022
Figure 3.11 Tissue Engineered Products Market: Drivers and Restraints, 2012-2022
Figure 3.12 Tissue Engineered Products: Market Forecast ($m), 2011-2022
Figure 3.13 Orthobiologics Market: Segment Market Shares (%), 2011
Figure 3.14 Osteocel Plus Revenue Forecast ($m), 2011-2022
Figure 3.15 Stem Cell Therapy: Market Forecast ($m), 2011-2022
Figure 3.16 Stem Cell Therapy Market: Drivers and Restraints, 2012-2022
Figure 3.17 Gene Therapy: Market Forecast ($m), 2011-2022
Figure 3.18 Gene Therapy Market: Driver and Restraints, 2012-2022
Figure 3.19 Other Cell Therapy Products: Market Forecast ($m), 2011-2022
Figure 4.1 Avita Medical Regenerative Medicine Revenue ($m), 2009-2011
Figure 4.2 Genzyme: Carticel, Epicel and MACI Global Sales ($m), 2009-2011
Figure 4.3 TiGenix Product Sales ($m), 2009-2010
Figure 6.1 Regenerative Medicine: Drivers, 2012-2022
Figure 6.2 Regenerative Medicine: Restraints, 2012-2022
Figure 6.3 CIRM Funding by Disease, 2004-2011
Figure 7.1 Regenerative Medicine: World Market Forecast by Region ($m), 2011-2022
Figure 7.2 Regenerative Medicine: World Market Shares by Region (%), 2011
Figure 7.3 Regenerative Medicine: World Market Shares by Region (%), 2017
Figure 7.4 Regenerative Medicine: World Market Shares by Region (%), 2022
Figure 7.5 CBER Regenerative Medicine Regulation, 2012
Figure 7.6 US Regenerative Medicine Market: Drivers and Restraints, 2012-2022
Figure 7.7 US Regenerative Medicine: Market Forecast ($m), 2011-2022
Figure 7.8 European Regenerative Medicine Market: Drivers and Restraints, 2012-2022
Figure 7.9 Regenerative Medicine in Europe: Market Forecast ($m), 2011-2022
Figure 7.10 Asia Pacific Regenerative Medicine: Market Forecast ($m), 2011-2022
Figure 7.11 Asia Pacific Regenerative Medicine Market: Drivers and Restraints, 2012-2022
Figure 7.12 Rest of World Regenerative Medicine: Market Forecast ($m), 2011-2022

COMPANIES LISTED

Aastrom Biosciences
Advanced BioHealing
Advanced Cell Technology
Advanced Technologies and Regenerative Medicine
Aldagen
AlloSource
AlphaTec Spine
ALS Therapy Development Institute (US)
Altrika
Amedica
American Academy of Ophthalmology
Amgen
Amorcyte
Amsterdam Molecular Therapeutics (AMT)
AnGes MG
Angioblast Systems
Angiotech
AnorMED
Anterogen
Apceth
ArBlast
ARCH Venture Partners
Ark Therapeutics
AstraZeneca
Athersys
Avita Medical
AxoGen
Baxter Healthcare
Baylor College of Medicine
Beike Biotechnology
Benda Pharmaceutical
Beth Israel Deaconess Medical Center
BioD LLC
BioDlogics
Biogenea Pharmaceuticals
Bioheart
BioMed Realty Trust
BioSante Pharmaceuticals
BioTime
BioTissue
bluebird bio
Boehringer Ingelheim
BrainStorm
BresaGen
Brown University
California Institute of Regenerative Medicine (CIRM)
Canaan Partners
Capricor
Cardio3 BioSciences
Cardiogenesis Corporation
Catalan Institution for Research and Advanced Studies
Cellartis
CellCoTec
Cellerant Therapeutics
Cellerix
Cellonis Biotechnology
CellSeed
Center for Commercialization of Regenerative Medicine (Canada)
Center for Medicare and Medicaid Services (US)
Cephalon
Ceregene
CHA Biotech
Cha General Hospital, Seoul
Children's Hospital of Philadelphia
Chinese Academy of Sciences
Chinese Ministry of Science and Technology
Clinical Cell Culture
co.don AG
Cold Genesys
Committee for Advanced Therapies (CAT)
Crawford Healthcare
Cryo Center Saint-Petersburg
CyThera
Cytori Therapeutics
Daiichi Sankyo
Dendreon
Department of Health (UK)
DePuy Mitek
Drugs Controller General of India (DCGI)
Eli Lilly
Emory University
Epeius Biotechnologies
European Medicines Agency (EMA)
EyeCyte
FCB-Pharmicell
Fibrocell Science
Food and Drug Administration (US FDA)
Forbion Capital Partners
Gamida Cell
Garnet Biotherapeutics
Gemabank
Genentech
Genethon
Genetic Engineering Approval Committee (GEAC)
GenVec
Genzyme
Geron
Geron Bio-Med
GlaxoSmithKline
Hadassah Medical Organization
Harvard Medical School
Health Canada
Hefei Meifu Bio-Tech
Histogenics
Humacyte
Human Stem Cell Institute
Ilika
ImmunoCellular Therapeutics
Integra
Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
International Society for Stem Cell Research (ISSCR)
Introgen
ISTO Technologies
Ixion Biotechnology
Japan Patent Office (JPO)
Japanese Society for Regenerative Medicine (JSRM)
Japanese Tissue Engineering Co
Jennerex Biotherapeutics
John Hopkins Cancer Centre
Johnson & Johnson (J&J)
Juvenile Diabetes Research Foundation (JDRF)
Kanazawa University
Kinetic Concepts
Kobe Pharmaceutical University
Korea Food and Drug Administration (KFDA)
LecTec Corporation
LifeCell
Lonza
Lund University Stem Cell Center
Massachusetts Institute of Technology (MIT)
Massey Cancer Center, Virginia Commonwealth University
Medical Research Council (UK)
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
Medipost
MediStem
Medtronic
Merck & Co.
Merck Millipore (a division of Merck KGaA)
Mesoblast
Ministry of Health (China)
Ministry of Health, Labour and Welfare (MHLW) Japan
MolMed
Moorfields Eye Hospital (UK)
Motor Neurone Disease Association (MNDA, UK)
Muscular Dystrophy Association (US)
Musculoskeletal Transplant Foundation
Myriad Genetics
Mytogen
Nagoya University
National Cancer Institute
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
National Tissue Engineering Center (NTEC) China
NeoStem
Neuralstem
Neurologix
Nippon Zoki Pharmaceutical
Northern Therapeutics
Northwestern University
Novartis
Novo Nordisk
Novocell
NuVasive
OJSC HSCI (Human Stem Cells Institute)
OncoCyte
Opexa Therapeutics
OrbusNeich
Organ Procurement and Transplantation Network (OPTN)
Organogenesis
Orthofix
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pervasis Therapeutics
Pfizer
Pharmacells
Pharmaceutical and Medical Devices Agency (PMDA) Japan
Philippines Bureau of Food and Drugs
Pluristem Therapeutics
ProChon Biotech
PsiOxus Therapeutics
Queen's University Belfast
RegenTec
Reliance Life Sciences
ReNeuron
Review Committee of Genetic Manipulation (RCGM)
Roche
Russian Ministry of Healthcare and Social Development
Rutgers University
Safeguard Scientifics
Sanofi
Saudi Food and Drug Authority (SFDA)
Shanghai Qisheng
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Shire Pharmaceuticals
Shire Regenerative Medicine
Skye Orthobiologics
Southern General Hospital (Scotland)
SpineSmith Partners
St. Jude's Children Research Hospital
State Food and Drug Administration (SFDA) China
Stem Cell Research Center, Peking University
StemCells
StemGen
Stempeutics Research
SUNY Upstate Medical University (Japan)
SynBio
Takara Bio
Targeted Genetics Corporation
TCA Cellular Therapy
Tel Aviv University
Tengion
Texas Heart Institute
Third Rock Ventures
TiGenix
Tissue Genesis
Translational Research Informatics Center (Foundation for Biomedical Research and Innovation)
TVM Capital
UniQure
University College London (UCL)
University of California, Los Angeles (UCLA)
University of Copenhagen
University of Geneva
University of Glasgow
University of Leuven
University of Michigan
University of Modena Centre for Regenerative Medicine
University of Pennsylvania
University of York
US Department of Defense
US Government Accountability Office (USGAO)
ViaCyte
Vical
Vindon Scientific
Virginia Commonwealth University Massey Cancer Center
Visomed
Wake Forest Institute for Regenerative Medicine
Xcellerex
Xenetic Biosciences
Yonsei University
Zimmer
Enable